Global Companion Animal Cardiac Drugs Market Size Likely to Grow at a CAGR of 8.8% By 2035

The companion animal cardiac drugs market size in the world is estimated to be USD 1.24 billion in the year 2025 and is expected to grow from USD 1.37 billion in 2026 to about USD 3.18 billion by 2035 with a CAGR of 8.8% between the years 2026 and 2035.

Companion Animal Cardiac Drugs Market Revenue and Trends

Pharmaceutical products under the companion animal cardiac drugs market include ACE inhibitors, beta blockers, diuretics, pimobendan, antiarrhythmics, and vasodilators in the treatment of heart diseases in pets, in the majority of cases dogs and cats. The companion animal cardiac drugs market is experiencing a high rate of growth across the globe due to the rise in pet ownership and humanization trends, the rise of cardiac diseases in older companion animals, the rise in veterinary healthcare services, the growth in awareness of pet wellness, and the development of targeted therapies, combination regimens, and telemedicine integration across the globe.

What are the Factors That Have a Significant Contribution to the Growth of the companion animal cardiac drugs market?

Adoption has increased because of the growing demand for effective cardiac treatments due to the increase in pet adoption rates and life span as a result of pet humanization with owners spending on the advanced veterinary services provided like the human medicine. Reports on the industry show that up to 10 percent of elderly dogs and cats have cardiac problems, which have prompted the prescription of specialized medication. With increased obesity and stress in pets, veterinarians are in search of dependable and readily administered drugs that will enhance the quality of life and increase the longevity of pets.

There are extended release preparations, chewable formulations with flavor to enhance compliance, precise dosage through wearables and new molecules that have fewer side effects that have enhanced efficacy, adherence and outcomes. Other forces are increased prime responsibility in preventive cardiology, availability of better diagnostic measures such as echocardiography, and government/veterinary programs in the developed and emerging markets to support pet health programs.

Segment Insight

By Product Type

As of 2025, the largest share in the companion animal cardiac drugs market was held by products, including pimobendan and inodilators, which were posed to the market due to the demand in managing heart failure in dogs, providing them with positive inotropic and vasodilatory effects to enhance cardiac output. The drugs play a critical role in chronic therapy, symptom management, and the prolongation of survival, and the innovations in combination therapy and liquid preparations have been found to be of importance in increasing patient adherence and treatment success (which is becoming widely accepted among veterinarians as the key to success in treating animals).

By Distribution Channel

The greatest market share goes to the direct sales of veterinary pharmaceutical manufacturers through which they form the main channel of supplying through prescription, technical guidance and customizing dosage instructions. These services offer specialized consultations to institutions, regulatory services, and combined solutions to veterinary clinics, hospitals, and pet pharmacies to provide specialized care to the heart, thus being the choice of professionals working with complicated, long-term pet health processes.

Regional Insights

The companion animal cardiac drugs industry in North America is dominating the world market because of the high rate of pet ownership, the well-developed veterinary practice, the high expenditure on high-quality pet care and the early adoption of new and improved cardiac treatment. There is a high level of regulatory support, Big Pharma players, and cultural focus on pet wellness to keep the region in a constant state of innovation and market growth.

In the meantime, the companion animal cardiac drugs market in the Asia Pacific region is the fastest growing with pet adoption in urban families, pet care investment rising among the middle classes, veterinary clinics and the growing awareness of age related ailments. Alternative cheap effective cardiac drugs are gaining more and more uptake in countries such as China, India, and Japan being assisted by local production, the development of telemedicine, and the government pet health campaigns. The trends of urbanization, humanization of the pet, and increased distribution channels further increase market growth in the Asia Pacific.

Report Scope

Recent Developments

• In June 2025: Boehringer Ingelheim launched Vetmedin-CA1, an advanced chewable pimobendan formulation for cats with heart failure, featuring improved palatability and extended dosing intervals to enhance compliance in feline cardiac management.

List of the prominent players in the Companion Animal Cardiac Drugs Market:

• Boehringer Ingelheim Animal Health

• Elanco Animal Health Inc.

• Ceva Santé Animale

• Dechra Pharmaceuticals plc

• Zoetis Inc.

• Vetoquinol S.A.

• Norbrook Laboratories Ltd.

• Orion Corporation

• Anivive Lifesciences Inc.

• Bova Compounding (Australia)

• Kindred Biosciences (Elanco)

• Others

The Companion Animal Cardiac Drugs Market is segmented as follows:

By Drug Type

• Diuretics (Furosemide, Spironolactone, Torsemide, Hydrochlorothiazide)

• Positive Inotropes (Pimobendan, Digoxin)

• ACE Inhibitors (Enalapril, Benazepril, Ramipril, Imidapril)

• Beta-Blockers (Atenolol, Carvedilol, Metoprolol)

• Antiarrhythmics (Sotalol, Mexiletine, Amiodarone, Diltiazem)

• Calcium Channel Blockers (Amlodipine, Diltiazem)

• Aldosterone Antagonists

• Other Drug Types (Sildenafil, Omega-3 Supplements)

By Animal Type

• Dogs

• Cats

• Other Companion Animals (Ferrets, Rabbits)

By Disease Indication

• Myxomatous Mitral Valve Disease (MMVD)

• Congestive Heart Failure (CHF)

• Dilated Cardiomyopathy (DCM)

• Hypertrophic Cardiomyopathy (HCM — primarily feline)

• Cardiac Arrhythmias

• Systemic Hypertension with Cardiac Involvement

• Other Indications

By Distribution Channel

• Veterinary Hospitals & Clinics

• Retail Veterinary Pharmacies

• Online Veterinary Pharmacies

• Compounding Pharmacies

• Other Channels